New hope: 6-month TB drug combo tested in diabetic patients
NCT ID NCT07191834
First seen Sep 30, 2025 · Last updated May 09, 2026 · Updated 23 times
Summary
This study tests a 6-month treatment for drug-resistant tuberculosis in people with type 2 diabetes. Diabetes can make TB harder to treat, so researchers want to see if a new short-course drug combo (pretomanid, bedaquiline, linezolid, moxifloxacin) works as well and is as safe in diabetic patients as in non-diabetic ones. 60 participants aged 12 and older will be followed to check cure rates and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIFAMPICIN-RESISTANT/MULTIDRUG-RESISTANT PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.